Control of leucine-dependent mTORC1 pathway through chemical intervention of leucyl-tRNA synthetase and RagD interaction.
Kim, J.H., Lee, C., Lee, M., Wang, H., Kim, K., Park, S.J., Yoon, I., Jang, J., Zhao, H., Kim, H.K., Kwon, N.H., Jeong, S.J., Yoo, H.C., Kim, J.H., Yang J.S., Lee, M.Y., Lee, C.W., Yun, J., Oh, S.J., Kang, J.S., Martinis, S.A., Hwang, K.Y., Guo, M., Han, G., Han, J.M., and Kim, S.
Notes: These authors evaluated the effect of BC-LI-0186, a compound that inhibits leucine-dependent mTORC1 activity, on cell growth and death using human colon cancer SW620 cells. They showed that the compound inhibited growth of cancer cells expressing drug-resistant MTOR mutations. Cell viability and cytotoxicity were determined in SM620 cells stably expressing the red fluorescent protein CellPlayer™ NucLight Red (Essen BioScience) and treated with BC-LI-0186 diluted in media containing CellTox™ Green Dye (Promega). Viable (Red) and dead (green) signals were acquired every 2 h and quantification performed using an IncuCyte™ Zoom basic analyzer. (5043)
Expand Full Notes »